Effects of low-dose aspirin combined with letrozole on serum visfatin, monocyte chemoattractant protein-1 and pregnancy rate in patients with polycystic ovary syndrome

中国基层医药 Pub Date : 2020-03-15 DOI:10.3760/CMA.J.ISSN.1008-6706.2020.06.006

Xiaohe Wang, Qi Ma, Zhengyue Qian, Xiaoyan Pan

{"title":"Effects of low-dose aspirin combined with letrozole on serum visfatin, monocyte chemoattractant protein-1 and pregnancy rate in patients with polycystic ovary syndrome","authors":"Xiaohe Wang, Qi Ma, Zhengyue Qian, Xiaoyan Pan","doi":"10.3760/CMA.J.ISSN.1008-6706.2020.06.006","DOIUrl":null,"url":null,"abstract":"Objective \nTo study the effect of low-dose aspirin combined with letrozole on serum visfatin, monocyte chemoattractant protein-1(MCP-1) and pregnancy rate in patients with polycystic ovary syndrome(PCOS). \n \n \nMethods \nFrom November 2016 to November 2018, 110 patients with PCOS in the Third People's Hospital of Datong were selected.According to the random number table, they were divided into the observation group(60 cases) and the control group(50 cases). The control group was treated with letrozole, while the observation group was given letrozole combined with low-dose aspirin.The patients were continuously treated for 3 menstrual cycles.The changes of the serum visfatin, MCP-1, sex hormones, uterine artery blood flow before and after treatment, pregnancy and adverse reactions were compared between the two groups. \n \n \nResults \nAfter treatment, the serum visfatin, MCP-1, testosterone (T), luteinizing hormone (LH), LH/follicular estrogen (FSH), uterine arterial pulsation index (PI) and resistance index (RI) in the observation group were (11.03±2.17)ng/mL, (99.31±14.50)ng/L, (1.57±0.29)mmol/L, (6.57±1.30)U/L, (1.16±0.22), (1.07±0.24), (0.41±0.08), respectively, which were significantly lower than those in the control group[(15.57±2.56)ng/mL, (121.29±20.37)ng/L, (1.78±0.32)mmol/L, (8.40±1.88)U/L, (1.50±0.27), (1.45±0.29), (0.57±0.11)], the differences were statistically significant(t=10.068, 6.593, 3.608, 6.012, 7.278, 7.521, 8.815, all P 0.05). \n \n \nConclusion \nLow-dose aspirin combined with letrozole in the treatment of PCOS can effectively reduce the serum visfatin and MCP-1, regulate the sex hormones levels, improve uterine artery blood flow, improve pregnancy rate, and without increasing adverse drug reactions, so it's worthy of popularizing. \n \n \nKey words: \nPolycystic ovary syndrome; Aspirin; Letrozole; Drug therapy, combination; Visfatin; Monocyte chemoattractant proteins; Gonadal hormones; Uterine artery; Pregnancy","PeriodicalId":10226,"journal":{"name":"中国基层医药","volume":"27 1","pages":"665-669"},"PeriodicalIF":0.0000,"publicationDate":"2020-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国基层医药","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1008-6706.2020.06.006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective To study the effect of low-dose aspirin combined with letrozole on serum visfatin, monocyte chemoattractant protein-1(MCP-1) and pregnancy rate in patients with polycystic ovary syndrome(PCOS). Methods From November 2016 to November 2018, 110 patients with PCOS in the Third People's Hospital of Datong were selected.According to the random number table, they were divided into the observation group(60 cases) and the control group(50 cases). The control group was treated with letrozole, while the observation group was given letrozole combined with low-dose aspirin.The patients were continuously treated for 3 menstrual cycles.The changes of the serum visfatin, MCP-1, sex hormones, uterine artery blood flow before and after treatment, pregnancy and adverse reactions were compared between the two groups. Results After treatment, the serum visfatin, MCP-1, testosterone (T), luteinizing hormone (LH), LH/follicular estrogen (FSH), uterine arterial pulsation index (PI) and resistance index (RI) in the observation group were (11.03±2.17)ng/mL, (99.31±14.50)ng/L, (1.57±0.29)mmol/L, (6.57±1.30)U/L, (1.16±0.22), (1.07±0.24), (0.41±0.08), respectively, which were significantly lower than those in the control group[(15.57±2.56)ng/mL, (121.29±20.37)ng/L, (1.78±0.32)mmol/L, (8.40±1.88)U/L, (1.50±0.27), (1.45±0.29), (0.57±0.11)], the differences were statistically significant(t=10.068, 6.593, 3.608, 6.012, 7.278, 7.521, 8.815, all P 0.05). Conclusion Low-dose aspirin combined with letrozole in the treatment of PCOS can effectively reduce the serum visfatin and MCP-1, regulate the sex hormones levels, improve uterine artery blood flow, improve pregnancy rate, and without increasing adverse drug reactions, so it's worthy of popularizing. Key words: Polycystic ovary syndrome; Aspirin; Letrozole; Drug therapy, combination; Visfatin; Monocyte chemoattractant proteins; Gonadal hormones; Uterine artery; Pregnancy

查看原文本刊更多论文

小剂量阿司匹林联合来曲唑对多囊卵巢综合征患者血清内脂蛋白、单核细胞趋化蛋白-1及妊娠率的影响

目的研究小剂量阿司匹林联合来曲唑对多囊卵巢综合征（PCOS）患者血清内脂蛋白、单核细胞趋化蛋白-1（MCP-1）及妊娠率的影响。方法选择大同市第三人民医院2016年11月至2018年11月收治的110例多囊卵巢综合征患者。根据随机数表将其分为观察组（60例）和对照组（50例）。对照组给予来曲唑治疗，观察组给予来曲唑联合小剂量阿司匹林治疗。患者连续治疗3个月经周期。比较两组患者治疗前后血清内脂蛋白、MCP-1、性激素、子宫动脉血流量、妊娠及不良反应的变化。结果观察组治疗后血清内脂蛋白、MCP-1、睾酮（T）、促黄体生成素（LH）、促卵泡激素（FSH）、子宫动脉搏动指数（PI）和阻力指数（RI）分别为（11.03±2.17）ng/mL、（99.31±14.50）ng/mL，（1.57±0.29）mmol/L、（6.57±1.30）U/L、（1.16±0.22）、（1.07±0.24）和（0.41±0.08），显著低于对照组[（15.57±2.56）ng/mL，（121.29±20.37）ng/mL、（1.78±0.32）mmol/L、（8.40±1.88）U/L、（1.50±0.27）、（1.45±0.29）、（0.57±0.11）]，差异有统计学意义（t=10.068，6.593，3.608，6.012，7.278，7.521，8.815，均P<0.05），值得推广。关键词：多囊卵巢综合征；阿司匹林；来曲唑；药物治疗，联合用药；Visfatin；单核细胞趋化蛋白；性腺激素；子宫动脉；妊娠

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

中国基层医药

CiteScore

0.10

自引率

0.00%

发文量

32251

期刊介绍： Since its inception, the journal "Chinese Primary Medicine" has adhered to the development strategy of "based in China, serving the grassroots, and facing the world" as its publishing concept, reporting a large amount of the latest medical information at home and abroad, prospering the academic field of primary medicine, and is praised by readers as a medical encyclopedia that updates knowledge. It is a core journal in China's medical and health field, and its influence index (CI) ranks Q2 in China's academic journals in 2022. It was included in the American Chemical Abstracts in 2008, the World Health Organization Western Pacific Regional Medical Index (WPRIM) in 2009, and the Japan Science and Technology Agency Database (JST) and Scopus Database in 2018, and was included in the Wanfang Data-China Digital Journal Group and the China Academic Journal Comprehensive Evaluation Database.